


REMARKS

The instant application discloses 73 biological sequences, but due to an inadvertent administrative oversight, the Sequence Listing filed with the original application on February 27, 2002, disclosed only SEQ ID NOS: 1-72. The present Voluntary Amendment is therefore an effort to remedy this deficiency in good faith and without deceptive intent, by assigning a SEQ ID NO to the sequence disclosed in Figure 5 and setting forth all 73 sequences (SEQ ID NOS: 1-72 exactly as disclosed in the Sequence Listing filed with the original application and SEQ ID NO: 73 as disclosed in Figure 5 as filed in the original application) in the enclosed corrected Sequence Listing. Applicants believe the present Amendment places the application in compliance with 37 C.F.R. §§1.821-1.825 and WIPO Standard 25. As noted above, the identity of the sequence set forth in SEQ ID NO: 73 was disclosed in Figure 5 as filed in the original application. Hence, no new subject matter is being added by the incorporation of this Sequence Listing. Thus, applicants respectfully request that the enclosed Sequence Listing setting forth SEQ ID NOS: 1-73 be added to the specification in the above-identified application.

The enclosed electronic and paper copies of the Sequence Listing include no new matter that goes beyond the original application as filed. Furthermore, the above amendments, which merely direct the insertion of the Sequence Listing and insertion of sequence identifiers, include no matter that goes beyond the original application as filed. Applicants respectfully submit that the above-identified application is now in compliance with 37 C.F.R. §§ 1.821-1.825 and WIPO Standard ST. 25.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The first of the attached pages is captioned "Version with Markings to Show Changes Made."

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Stephen J. Rosenman, Ph.D.  
Registration No. 43,058



Application No. 10/083,815  
Docket No. 660088.435C2

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at page 20, line 7, has been amended as follows:

Figure 5 shows the amino acid sequence of rat IF1 (~~SEQ ID NO: 13~~) (SEQ ID NO: 73) and results from experiments in which two different synthetic polypeptides derived from rat IF1 were tested for their ability to inhibit purified F1-ATPase or F0-F1-ATPase.

SJR:mls

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031